Fujiwara Tomohiro, Healey John, Ogura Koichi, Yoshida Aki, Kondo Hiroya, Hata Toshiaki, Kure Miho, Tazawa Hiroshi, Nakata Eiji, Kunisada Toshiyuki, Fujiwara Toshiyoshi, Ozaki Toshifumi
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Cancers (Basel). 2021 Mar 3;13(5):1086. doi: 10.3390/cancers13051086.
Sarcomas are complex tissues in which sarcoma cells maintain intricate interactions with their tumor microenvironment. Tumor-associated macrophages (TAMs) are a major component of tumor-infiltrating immune cells in the tumor microenvironment and have a dominant role as orchestrators of tumor-related inflammation. TAMs promote tumor growth and metastasis, stimulate angiogenesis, mediate immune suppression, and limit the antitumor activity of conventional chemotherapy and radiotherapy. Evidence suggests that the increased infiltration of TAMs and elevated expression of macrophage-related genes are associated with poor prognoses in most solid tumors, whereas evidence of this in sarcomas is limited. Based on these findings, TAM-targeted therapeutic strategies, such as inhibition of CSF-1/CSF-1R, CCL2/CCR2, and CD47/SIRPα, have been developed and are currently being evaluated in clinical trials. While most of the therapeutic challenges that target sarcoma cells have been unsuccessful and the prognosis of sarcomas has plateaued since the 1990s, several clinical trials of these strategies have yielded promising results and warrant further investigation to determine their translational benefit in sarcoma patients. This review summarizes the roles of TAMs in sarcomas and provides a rationale and update of TAM-targeted therapy as a novel treatment approach for sarcomas.
肉瘤是复杂的组织,其中肉瘤细胞与其肿瘤微环境保持着复杂的相互作用。肿瘤相关巨噬细胞(TAM)是肿瘤微环境中肿瘤浸润免疫细胞的主要组成部分,作为肿瘤相关炎症的协调者发挥着主导作用。TAM促进肿瘤生长和转移,刺激血管生成,介导免疫抑制,并限制传统化疗和放疗的抗肿瘤活性。有证据表明,TAM浸润增加和巨噬细胞相关基因表达升高与大多数实体瘤的预后不良相关,而在肉瘤中的相关证据有限。基于这些发现,已经开发了针对TAM的治疗策略,如抑制CSF-1/CSF-1R、CCL2/CCR2和CD47/SIRPα,目前正在临床试验中进行评估。虽然大多数针对肉瘤细胞的治疗挑战都未成功,且自20世纪90年代以来肉瘤的预后一直停滞不前,但这些策略的几项临床试验已取得了有希望的结果,值得进一步研究以确定它们对肉瘤患者的转化效益。本综述总结了TAM在肉瘤中的作用,并为将针对TAM的治疗作为肉瘤的一种新型治疗方法提供了理论依据和最新进展。